Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Dicycloverine Oral Solution

Active Ingredient:
dicycloverine hydrochloride
ADVANZ Pharma See contact details
ATC code: 
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 24 Jan 2024
1. Name of the medicinal product

Dicycloverine Oral Solution

2. Qualitative and quantitative composition

Dicycloverine Hydrochloride 10mg/5ml

Excipient(s) with known effect

Each 5ml of oral solution contains

Sucrose: 2.33g

Sodium benzoate: 1.25mg

For the full list of excipients, see section 6.1

3. Pharmaceutical form


4. Clinical particulars
4.1 Therapeutic indications

Dicyloverine is a smooth muscle antispasmodic primarily indicated for treatment of functional conditions involving smooth muscle spasm of the gastrointestinal tract. The commonest of these are irritable colon (mucous colitis, spastic colon).

4.2 Posology and method of administration



One to two 5ml spoonfuls (10 - 20mg) three times daily before or after meals.

Children (2-12 years):

One 5ml spoonful (10mg) three times daily.

Children (6 months - 2 years)

5 - 10mg three or four times daily, 15 minutes before feeds. Do not exceed a daily dose of 40mg. If it is necessary to dilute Dicyloverine Oral Solution this may be done using Syrup or if diluted immediately prior to use with water.

Method of administration


4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known idiosyncrasy to dicycloverine hydrochloride. Infants under 6 months of age.

4.4 Special warnings and precautions for use

Products containing dicycloverine hydrochloride should be used with caution in any patient with or suspected of having glaucoma or prostatic hypertrophy. Use with care in patients with hiatus hernia associated with reflux oesophagitis because anticholinergic drugs may aggravate the condition. There are reports of infants, 3 months of age and under, administered dicycloverine hydrochloride syrup who have evidenced respiratory symptoms (breathing difficulty, shortness of breath, breathlessness, respiratory collapse, apnoea) as well as seizures, syncope, asphyxia, pulse rate fluctuations, muscular hypotonia and coma. The above symptoms have occurred within minutes of ingestion and lasted 20-30 minutes. The symptoms were reported in association with dicycloverine hydrochloride oral solution therapy but the cause and effect relationship has neither been disproved or proved. The timing and nature of the reactions suggest that they were a consequence of local irritation and/or aspiration, rather than to a direct pharmacological effect. Although no causal relationship between these effects, observed in infants and dicycloverine administration has been established, dicycloverine hydrochloride is contra-indicated in infants under 6 months of age.

Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorbtion or sucrase-isomaltase insufficiency should not take this medicine

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation


Epidemiological studies in pregnant women with products containing dicycloverine hydrochloride (at doses up to 40mg/day) have not shown that dicycloverine hydrochloride increases the risk of foetal abnormalities if administered during the first trimester of pregnancy. Reproduction studies have been performed in rats and rabbits at doses of up to 100 times the maximum recommended dose (based on 60mg per day for an adult person) and have revealed no evidence of impaired fertility or harm to the foetus due to dicycloverine. Since the risk of teratogenicity cannot be excluded with absolute certainty for any product, the drug should be used during pregnancy only if clearly needed.


It is not known whether dicycloverine is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when dicycloverine is administered to a nursing mother.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

The following adverse reactions are classified by system organ class and ranked under heading of frequency using the following convention:

Rare (≥ 1/10,000 to <1/1,000)

Not known: frequency cannot be estimated from the available data

MedDRA system organ class database


Adverse reactions

Nervous system disorders


Sedation, headache

Not known

Dizziness may occur

Metabolism and nutrition disorders



Eye disorders


Blurred vision

Gastrointestinal disorders

Not known

Dry mouth


Constipation, nausea, vomiting

Renal and urinary disorders



Skin and subcutaneous tissue disorders



General disorders and administration site conditions



Not known


Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose


Symptoms of Dicycloverine overdosage are headache, dizziness, nausea, dry mouth, difficulty in swallowing, dilated pupils and hot dry skin.


Treatment may include emetics, gastric lavage and symptomatic therapy if indicated.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for functional gastrointestinal disorders, ATC code: A03AA07

Dicycloverine hydrochloride relieves smooth muscle spasm of the gastrointestinal tract.

Animal studies indicate that this action is achieved via a dual mechanism;

(1) a specific anticholinergic effect (antimuscarinic at the ACh-receptor sites) and

(2) a direct effect upon smooth muscle (musculotropic).

5.2 Pharmacokinetic properties

Distribution and Biotransformation

After a single oral 20mg dose of dicycloverine hydrochloride in volunteers, peak plasma concentration reached a mean value of 58ng/ml in 1 to 1.5 hours. 14C labelled studies demonstrated comparable bioavailability from oral and intravenous administration.


The principal route of elimination is via the urine.

5.3 Preclinical safety data

Not relevant.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium benzoate

Sucrose (40-80#)

Citric acid monohydrate

Sodium Citrate

Flavour Cherry – ST4545/25

Flavour Raspberry – AF – 2283

Flavour Vanilla – AF – 2268

Flavour Blackcurrant – AF – 2285

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Do not store above 25° C. Store in the original container.

6.5 Nature and contents of container

Type III, EP amber glass bottles sealed with a polyethylene screw cap equipped with a polyethylene seal and pilferproof closure.

Pack size: 1 bottle containing 120ml syrup.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Focus Pharmaceuticals limited

Dashwood House

69 Old Broad Street




8. Marketing authorisation number(s)

PL 20046/0287

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text






Company image
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
+44 (0)208 588 9131
Medical Information Direct Line
+44 (0)208 588 9131
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 588 9273